EMJ Urology 10 [Supplement 2] . 2022

In this issue

As part of the 37th Annual European Association of Urology (EAU) Congress, this symposium presented key data from the CLEAR study: a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (RCC) in the first-line (1L) setting. Leading experts discussed strategies for optimising treatment outcomes in RCC using lenvatinib plus pembrolizumab and considered how to identify the right patients for this combination therapy in clinical practice.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given